The MarketWatch News Department was not involved in the creation of this content. PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company ...
Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria's proprietary Senza5 platform that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback